J Korean Diabetes > Volume 17(1); 2016 > Article
The Journal of Korean Diabetes 2016;17(1):51-59.
DOI: https://doi.org/10.4093/jkd.2016.17.1.51    Published online April 12, 2016.
15 mg Pioglitazone 투여로 혈당이 조절되지 않는 제2형 당뇨병 환자에서 Pioglitazone 증량이 혈당 조절에 미치는 효과에 대한 후향적, 관찰연구
하소영, 정해원, 최용준, 이현교, 최종욱, 최지훈, 노정현, 홍재원, 김동준
Retrospective Observational Dose-Titration Study of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on 15 mg of Pioglitazone.
So Young Ha, Hae Won Jung, Yong Jun Choi, Hyun Kyo Lee, Jong Wook Choi, Ji Hoon Choi, Jung Hyun Noh, Jae Won Hong, Dong Jun Kim
Department of Internal Medicine, Inje University Ilsan-Paik Hospital, Goyang, Korea. djkim@paik.ac.kr
Abstract
BACKGROUND
The 30 mg pioglitazone tablet was recently introduced in Korea; no study has yet compared its glucose-lowering or weight gain effects to the 15 mg tablet in Korean patients with type 2 diabetes mellitus (T2DM). METHODS: The electronic medical records of 45 patients with T2DM with glycated hemoglobin (HbA1c) levels > 7.0%, despite taking 15 mg/day pioglitazone and a stable dose of other diabetes drugs for 3 months, were retrospectively reviewed. RESULTS: After dose up-titration, HbA1c levels decreased at 3- and 6-month follow-ups compared with baseline (8.5% at baseline vs. 8.2% at 3 months vs. 7.9% at 6 months; baseline vs. 3 months, P = 0.106; baseline vs. 6 months, P = 0.005; 3 months vs. 6 months, P = 0.096). In the subgroup analysis of 36 patients taking pioglitazone, sulfonylurea, and metformin, HbA1c levels also decreased at 3- and 6-month follow-ups compared with baseline (8.5 % vs. 8.2 % vs. 7.9%; baseline vs. 3 months, P = 0.289; baseline vs. 6 months, P = 0.014; 3 months vs. 6 months, P = 0.232). There was no significant body weight change (70.8 kg vs. 70.7 kg vs. 71.0 kg). CONCLUSION: Up-titrating from 15 mg to 30 mg of pioglitazone in patients with inadequate glycemic control (HbA1c > 9%) who were also taking sulfonylurea and metformin showed additive glucose-lowering effects without significant weight gain in Korean patients with T2DM.
Key Words: Body weight, Diabetes mellitus, Glycated hemoglobin, Thiazolidinediones
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 1,502 View
  • 13 Download
Related articles


Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer